Clinical trial NCT05338970: HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Official title: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Nonsquamous Non-small Cell Lung Cancer
EGFR L858R
EGFR Exon 19 Deletion
Keywords: Nonsquamous Non-small Cell Lung Cancer
EGFR L858R
EGFR exon 19 deletion
Patritumab deruxtecan
HER3-DXd
U3-1402
Lead sponsor: Daiichi Sankyo
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2022-04-21
Enrollment: 586
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.

Detailed description: Patritumab deruxtecan (HER3-DXd, U3-1402) is an antibody-drug conjugate (ADC) comprising an anti-HER3 mAb linked to a topoisomerase I inhibitor that is in clinical development for patients with NSCLC, metastatic breast cancer, and colorectal cancer.

The primary objective of the current study is to compare the efficacy of patritumab deruxtecan versus platinum-based chemotherapy, as measured by progression-free survival (PFS) and the key secondary endpoint of overall survival (OS), in participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) after failure of third-generation (eg, osimertinib, lazertinib, aumolertinib, alflutinib) EGFR TKI therapy.

Eligibility criteria: Inclusion Criteria:

1. Is a male or female subject aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \>18 years old).
2. Has histologically or cytologically documented metastatic or locally advanced non-squamous NSCLC not amenable to curative surgery or radiation.
3. Has documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R at diagnosis or thereafter.
4. Received 1 or 2 prior line(s) of an approved EGFR TKI treatment in the metastatic or locally advanced setting, which must include a third -generation EGFR TKI
5. May have received either neoadjuvant and/or adjuvant treatment if progression to metastatic or locally advanced disease occurred at least 12 months after the last dose of such therapy and subsequently experienced disease progression on or after third-generation EGFR TKI treatment administered in the metastatic or locally advanced setting.
6. Has not received any other prior systemic therapies in the metastatic or locally advanced setting (including chemotherapy, immunotherapy etc) (even if administered in combination with EGFR TKI).
7. Has documentation of radiographic disease progression while receiving or after receiving a third generation EGFR TKI for metastatic or locally advanced disease.
8. Has at least 1 measurable lesion as per RECIST v1.1 by Investigator assessment.
9. Is willing to have a tumor biopsy or provide recently obtained tumor tissue.
10. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.
11. Has adequate bone marrow reserve and organ function based on local laboratory evaluation within 14 days prior to randomization:

    * Platelet count: ≥100,000/mm\^3 or ≥100 × 10\^9/L within 14 days prior to the assessment of platelet count during the Screening Period
    * Absolute neutrophil count: ≥1500/mm\^3 or ≥1.5 × 10\^9/L within 14 days prior to the assessment of absolute neutrophil count during the Screening Period
    * Hemoglobin (Hgb): ≥9.0 g/dL within 14 days prior to the assessment of hemoglobin during the Screening Period
    * Creatine clearance (CrCl): CrCl ≥45 mL/min calculated by using the Cockcroft-Gault equation or measured CrCl
    * Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT): AST/ALT ≤3× Upper limit of normal (ULN)
    * Total bilirubin (TBL): TBL ≤1.5 × ULN
    * Serum albumin: ≥2.5 g/dL
    * Prothrombin time (PT) or Prothrombin time-International normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT)/partial thromboplastin time (PTT): ≤1.5 × ULN, except for participants receiving coumarin-derivative anticoagulants or other similar anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator

Exclusion Criteria:

1. Has any previous histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the archival tumor tissue or pretreatment tumor biopsy, or squamous NSCLC histology
2. Has any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during Screening
3. Has clinically severe respiratory compromise (based on the Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to the following:

   * Any underlying pulmonary disorder, restrictive lung disease, or pleural effusion
   * Any autoimmune, connective tissue, or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of Screening
   * OR prior complete pneumonectomy
4. Is receiving chronic systemic corticosteroids dosed at \>10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to randomization
5. Has any history of or evidence of current leptomeningeal disease
6. Has evidence of clinically active spinal cord compression or brain metastases, defined as being symptomatic and untreated, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
7. Any prior treatment with any agent including an antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I, human epidermal growth factor receptor 3 (HER3) antibody, and any systemic therapies (other than EGFR TKIs) in the metastatic/locally advanced setting, including chemotherapy or any other systemic therapy in combination with an EGFR TKI
8. Has history of other active malignancy within 3 years prior to randomization, except for adequately resected nonmelanoma skin cancer, adequately treated intraepithelial carcinoma of the cervix, and any other curatively treated in situ disease
9. Has uncontrolled or significant cardiovascular disease prior to randomization
10. Has active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of active viral infection within 28 days of randomization
11. Has a known human immunodeficiency virus (HIV) infection that is not well controlled
12. Has clinically significant corneal disease

Primary outcomes:
measure: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: Baseline up to approximately 49 months
measure: Progression-free Survival (PFS) as Assessed by Investigator Review Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
measure: Progression-free Survival (PFS) as Assessed by Local Standard Clinical Practice
timeFrame: Baseline up to approximately 49 months
measure: Objective Response Rate (ORR) as Assessed by BICR and Investigator Review Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
measure: Duration of Response (DoR) as Assessed by BICR and Investigator Review Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
measure: Clinical Benefit Rate (CBR) as Assessed by BICR and Investigator Review Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
measure: Disease Control Rate (DCR) as Assessed by BICR and Investigator Review Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
measure: Time to Response (TTR) as Assessed by BICR and Investigator Review Based on RECIST v1.1
timeFrame: Baseline up to approximately 49 months
measure: Intracranial PFS as Assessed by BICR
timeFrame: Baseline up to approximately 49 months
measure: Mean Change from Baseline in Non-small Cell Lung Cancer - Symptom Assessment Questionnaire
timeFrame: Baseline up to approximately 49 months
measure: Mean Change from Baseline in Patient's Global Impression of Change
timeFrame: Baseline up to approximately 49 months
measure: Mean Change from Baseline in Patient's Global Impression of Severity
timeFrame: Baseline up to approximately 49 months
measure: Mean Change from Baseline in Patient's Global Impression of Treatment Tolerability
timeFrame: Baseline up to approximately 49 months
measure: Mean Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
timeFrame: Baseline up to approximately 49 months
measure: Mean Change from Baseline in EuroQol Questionnaire-5 dimensions-5 levels (EQ-5D-5L)
timeFrame: Baseline up to approximately 49 months
measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
timeFrame: Baseline up to approximately 49 months
measure: Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)
timeFrame: Baseline up to approximately 49 months
measure: Percentage of Participants Who Have Treatment-emergent ADA
timeFrame: Baseline up to approximately 49 months
Other outcomes:
Locations:
city: Anchorage
country: United States
facility: Alaska Oncology and Hematology LLC
state: Alaska
city: Springdale
country: United States
facility: Highlands Oncology
state: Arkansas
city: Duarte
country: United States
facility: City of Hope
state: California
city: La Jolla
country: United States
facility: Moores Cancer Center at the UC San Diego Health
state: California
city: La Jolla
country: United States
facility: Scripps MD Anderson Cancer Center
state: California
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center
state: California
city: Vallejo
country: United States
facility: Kaiser Permanente - Vallejo Medical Center
state: California
city: Whittier
country: United States
facility: Innovative Clinical Research Institute
state: California
city: Port Charlotte
country: United States
facility: Sarah Cannon/Florida Cancer Specialists - FCS South
state: Florida
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Boise
country: United States
facility: St Luke's Cancer Institute
state: Idaho
city: Bethesda
country: United States
facility: American Oncology Partners of Maryland
state: Maryland
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Lebanon
country: United States
facility: Dartmouth Hitchcock Medical Center
state: New Hampshire
city: Manahawkin
country: United States
facility: Hackensack Meridian Health-Southern Ocean Medical Center
state: New Jersey
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Portland
country: United States
facility: Providence Portland Medical Center
state: Oregon
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: Dallas
country: United States
facility: University of Texas Southwestern Medical Center
state: Texas
city: Fairfax
country: United States
facility: Inova Schar Cancer Institute
state: Virginia
city: Fairfax
country: United States
facility: Virginia Cancer Specialists
state: Virginia
city: Madison
country: United States
facility: University of Wisconsin Carbone Cancer Center
state: Wisconsin
city: Camperdown
country: Australia
facility: The Chris O'Brien Lifehouse
city: Kogarah
country: Australia
facility: St George Public Hospital
city: Liverpool
country: Australia
facility: Liverpool Hospital
city: Melbourne
country: Australia
facility: Austin Hospital
city: Subiaco
country: Australia
facility: St John of God Subiaco Hospital
city: Woolloongabba
country: Australia
facility: Princess Alexandra Hospital
city: Feldkirch
country: Austria
facility: Landeskrankenhaus Feldkirch
city: Innsbruck
country: Austria
facility: Medizinische Universitaet Innsbruck
city: Klagenfurt
country: Austria
facility: Klinikum Klagenfurt Pulmologie
city: Wels
country: Austria
facility: Klinikum Wels-Grieskirchen
city: Wien
country: Austria
facility: Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc
city: Leuven
country: Belgium
facility: UZ Leuven
city: Mechelen
country: Belgium
facility: AZ Sint Maarten Mechelen
city: Roeselare
country: Belgium
facility: AZ Delta
city: Brampton
country: Canada
facility: William Osler Health System - Brampton Civic Hospital
city: Beijing
country: China
facility: Peking University Cancer Hospital
city: Chang chun
country: China
facility: Jilin Cancer Hospital
city: Changsha
country: China
facility: Hunan Cancer Hospital
city: Chengdu
country: China
facility: University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute Sichuan Provincial Tumor Hospital
city: Chibi
country: China
facility: National Cancer Center Hospital East
city: Fuzhou
country: China
facility: Fujian Medical University - Union Hospital Foochow Christian Union Hospital
city: Guangzhou
country: China
facility: Guangdong Academy of Medical Science (GAMS) - Guangdong Provincial Peoples Hospital
city: Guangzhou
country: China
facility: The First Affiliated Hospital Sun-Yat-Sen University
city: Haidian
country: China
facility: Pecking University Third Hospital
city: Hangzhou
country: China
facility: The First Affiliated Hospital of College of Medicine Zhejiang University
city: Hangzhou
country: China
facility: Zhejiang Cancer hospital
city: Harbin
country: China
facility: Harbin Medical University - Tumor Hospital The Third Affiliated Hospital
city: Hefei
country: China
facility: The First Affiliated Hospital - Anhui Medical University Dept of Medical Oncology
city: Henan
country: China
facility: Henan Provincial Peoples Hospital
city: Kunming
country: China
facility: The Second Affiliated Hospital of Kunming Medical University
city: Linyi
country: China
facility: Lin Yi Cancer Hospital
city: Nanjing
country: China
facility: General Hospital of Eastern Theater Command
city: Nanning
country: China
facility: The First Affiliated Hospital of Guangxi Medical University
city: Shanghai
country: China
facility: Fudan University - Shanghai Cancer Center FUSCC
city: Shantou
country: China
facility: Cancer Hospital of Shantou University Medical College
city: Shenyang
country: China
facility: The First Hospital of China Medical University
city: Wuhan
country: China
facility: Union Hospital of Tongji Medical College Huazhong University of Science and Technology
city: Wuhan
country: China
facility: Huazhong University of Science and Technology - Tongji Medical College - Tongji Hospital TJH
city: Xi'an
country: China
facility: The First Affiliate Hospital of Xi'an Jiaotong University
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Ürümqi
country: China
facility: Affiliated Cancer Hospital of Xinjiang Medical University
city: Brest
country: France
facility: Hopital Morvan CHU de Brest
city: Caen
country: France
facility: Centre Francois Baclesse
city: Caen
country: France
facility: Centre Francois Baclesse
city: Lyon
country: France
facility: Centre Leon Berard
city: Montpellier
country: France
facility: Montpellier Cancer Institute ICM
city: Paris Cedex 05
country: France
facility: Institut Curie
city: Paris
country: France
facility: APHP - Hopital Saint Louis
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud
city: Rennes
country: France
facility: Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou
city: Saint-Herblain
country: France
facility: Institut de Cancrologie de lOuest ICO
city: Villejuif
country: France
facility: Gustave Roussy
city: Essen
country: Germany
facility: Universitaetsklinikum Essen
city: Esslingen
country: Germany
facility: Klinikum Esslingen GmbH
city: Frankfurt am main
country: Germany
facility: IKF Krankenhaus Nordwest
city: Gauting
country: Germany
facility: Asklepios Fachklinik Muenchen-Gauting
city: Gießen
country: Germany
facility: Universitatsklinik Giessen und Marburg
city: Großhansdorf
country: Germany
facility: LungenClinic Grosshansdorf
city: Heidelberg
country: Germany
facility: Thoraxklinik Heidelberg gGmbH
city: Immenhausen
country: Germany
facility: LKI Lungenfachklinik Immenhausen
city: Kempten
country: Germany
facility: Klinikverbund Allgaeu
city: Oldenburg
country: Germany
facility: Pius-Hospital Oldenburg
city: Hong Kong
country: Hong Kong
facility: Pamela Youde Nethersole Eastern Hospital
city: Hong Kong
country: Hong Kong
facility: Prince of Wales Hospital
city: Hong Kong
country: Hong Kong
facility: University of Hong Kong/Queen Mary Hospital
city: Hong Kong
country: Hong Kong
facility: Queen Elizabeth Hospital
city: Bari
country: Italy
facility: IRCCS Istituto Oncologico Giovanni Paolo II
city: Chieti
country: Italy
facility: University G. D'Annunzio Chieti
city: Lucca
country: Italy
facility: Ospedale San Luca
city: Milano
country: Italy
facility: IRCCS Istituto Europeo di Oncologia
city: Milano
country: Italy
facility: Asst Grande Ospedale Metropolitano Niguarda
city: Orbassano
country: Italy
facility: Azienda Ospedaliero-Universitaria San Luigi Gonzaga
city: Parma
country: Italy
facility: Azienda Ospedaliero Universitaria di Parma
city: Perugia
country: Italy
facility: Ospedale Santa Maria della Misericordia
city: Roma
country: Italy
facility: IFO Regina Elena
city: Rozzano
country: Italy
facility: IRCCS Humanitas Research Hospital
city: Varese
country: Italy
facility: ASST Sette Laghi
city: Akashi
country: Japan
facility: Hyogo Cancer Center
city: Fukuoka
country: Japan
facility: Kyushu University Hospital
city: Hidaka
country: Japan
facility: Saitama Medical University International Medical Center
city: Hirakata
country: Japan
facility: Kansai Medical University Hospital
city: Iwakuni
country: Japan
facility: Iwakuni Clinical Center
city: Izumi
country: Japan
facility: Izumi City General Hospital
city: Kanazawa
country: Japan
facility: Kanazawa University Hospital
city: Koto-Ku
country: Japan
facility: The Cancer Institute Hospital of JFCR
city: Kumamoto
country: Japan
facility: Saiseikai Kumamoto Hospital
city: Kurashiki
country: Japan
facility: Kurashiki Central Hospital
city: Kurume
country: Japan
facility: Kurume University Hospital
city: Matsusaka
country: Japan
facility: Matsusaka Municipal Hospital
city: Matsuyama
country: Japan
facility: NHO Shikoku Cancer Center
city: Nagoya
country: Japan
facility: National Hospital Organization Nagoya Medical Center
city: Niigata
country: Japan
facility: Niigata Cancer Center Hospital
city: Okayama
country: Japan
facility: Okayama University Hospital
city: Sapporo
country: Japan
facility: National Hospital Organization Hokkaido Cancer Center
city: Sendai
country: Japan
facility: Sendai Kousei Hospital
city: Tokyo
country: Japan
facility: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
city: Toyoake
country: Japan
facility: Fujita Health University Hospital
city: Wakayama
country: Japan
facility: Wakayama Medical University Hospital
city: Ōsaka-sayama
country: Japan
facility: Kindai University Hospital
city: Cheongju-si
country: Korea, Republic of
facility: Chungbuk National University Hospital
city: Goyang
country: Korea, Republic of
facility: National Cancer Center
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Marys Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Amsterdam
country: Netherlands
facility: Netherlands Cancer Institute
city: Arnhem
country: Netherlands
facility: Rijnstate Ziekenhuis
city: Harderwijk
country: Netherlands
facility: St. Jansdal Ziekenhuis
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
city: Rotterdam
country: Netherlands
facility: Erasmus MC
city: Utrecht
country: Netherlands
facility: University Medical Center Utrecht
city: Nordbyhagen
country: Norway
facility: Akershus University Hospital
city: Oslo
country: Norway
facility: Oslo University Hospital-The Norwegian Radium Hospital
city: Stavanger
country: Norway
facility: Stavanger University Hospital
city: Białystok
country: Poland
facility: II Klinika Chorob Pluc i Gruzlicy
city: Lublin
country: Poland
facility: Onko-Centrum Sp. z o.o.
city: Poznań
country: Poland
facility: Med Polonia Sp. z o.o.
city: Lisboa
country: Portugal
facility: Centro Clinico Champalimaud
city: Lisbon
country: Portugal
facility: Instituto Portugues de Oncologio de Lisboa
city: Porto
country: Portugal
facility: Centro Hospitalar Universitario do Porto - Hospital de Santo Antonio
city: Porto
country: Portugal
facility: Centro Hospitalar de Vila Nova de Gaia - Espinho
city: Singapore
country: Singapore
facility: National University Cancer Institute National University Hospital
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore NCCS
city: Singapore
country: Singapore
facility: Tan Tock Seng Hospital
city: Singapore
country: Singapore
facility: ICON Cancer Centre
city: A Coruña
country: Spain
facility: Hospital Teresa Herrera C.H.U.A.C.
city: Barcelona
country: Spain
facility: Hospital del Mar
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron
city: Barcelona
country: Spain
facility: Hospital Clinic i Provincial de Barcelona
city: Las Palmas De Gran Canaria
country: Spain
facility: Complejo Hospitalario Materno-Insular - Hospital Insular de Gran Canaria
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Maranon
city: Madrid
country: Spain
facility: MD Anderson Cancer Center
city: Madrid
country: Spain
facility: Hospital Universitario Fundacion Jimenez Diaz
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Málaga
country: Spain
facility: Hospital Regional Universitario Malaga
city: Santander
country: Spain
facility: Hospital Univeritario Marques de Valdecilla
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Chur
country: Switzerland
facility: Kantonsspital Graubuenden - Hauptstandort
city: Winterthur
country: Switzerland
facility: Kantonsspital Winterthur KSW
city: Kaohsiung City
country: Taiwan
facility: E-Da Hospital
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital NCKUH
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital NTUH
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taoyuan
country: Taiwan
facility: Chang Gung Memorial Hospital-Linkou Branch
city: Birmingham
country: United Kingdom
facility: University Hospital Birmingham NHS Trust
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: Leeds
country: United Kingdom
facility: Leeds Cancer Centre
city: Leicester
country: United Kingdom
facility: University Hospitals of Leicester
city: London
country: United Kingdom
facility: Barts and The London NHS Trust - St Bartholomew s hospital - PET CT Centre
city: London
country: United Kingdom
facility: The Royal Marsden Hospital NHS Foundation Trust
city: London
country: United Kingdom
facility: The Royal Marsden NHS Foundation Trust
city: Manchester
country: United Kingdom
facility: The Christie Hospital
city: Wolverhampton
country: United Kingdom
facility: The Royal Wolverhampton NHS Trust
Study officials:
affiliation: Daiichi Sankyo
name: Global Clinical Leader
role: STUDY_DIRECTOR
affiliation: Daiichi Sankyo
name: Clinical Scientist
role: STUDY_CHAIR
References: